منابع مشابه
SLE - Rituximab in lupus
B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, a...
متن کاملUse of Rituximab in child with SLE and myocardial involvement
Three years into diagnosis she had symptoms of increasing tiredness, breathlessness and tachycardia. An echocardiogram confirmed ventricular dilatation suggesting myocardial involvement. She was recommenced on Cyclophosphamide with Methyprednisolone, and was also commenced on Frusemide and Enalapril which initiated control of her cardiac function. Her ejection fraction improved from 30% to 52%....
متن کاملRituximab therapy improves recalcitrant Pemphigus vulgaris
Pemphigus is a severe life-threatening blistering disease associated with autoantibodies against cell adhesion proteins desmogleins 1 and 3. Patients with severe pemphigus commonly show high rates of relapse after conventional immunosuppressive therapy. The newly developed drug Rituximab showed impressing promises in the treatment of refractory pemphigus vulgaris (PV). In the present study the ...
متن کاملisolated hematuria in sle patients and its association with proteinuria, uri-nary cast and sle disease activity
isolated hematuria and its association with proteinuria, and urinary cast and systemic lupus erythematosus (sle) disease activity, and decision for renal biopsy is a dilemma for physician in sle patients. the aim of this study was to investigate 1. whether isolated hematuria is associated with active sle, 2. to determine duration between hematuria and proteinuria and urinary cast, and 3. to det...
متن کاملRituximab-induced lung disease.
Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been reported and may cause mortality despite early detection. Typically the pulmonary toxicity occurs at around the fourth cycle of Rituximab. High index of suspicion is crucial and other concurrent patholo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Rheumatology
سال: 2017
ISSN: 1759-4790,1759-4804
DOI: 10.1038/nrrheum.2017.212